With DPP4 inhibitors as a comparator previously shown to have neutral effects on cognition [10, 11], the present study demonstrates that SGLT2 inhibitors may reduce dementia risk in adults with type 2 diabetes aged ≥ 60 years, but the association between the study GLP1 receptor agonists and dementia risk reduction is less certain. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.